MX2010004892A - Terapia de combinacion para tratar infecciones virales persistentes. - Google Patents

Terapia de combinacion para tratar infecciones virales persistentes.

Info

Publication number
MX2010004892A
MX2010004892A MX2010004892A MX2010004892A MX2010004892A MX 2010004892 A MX2010004892 A MX 2010004892A MX 2010004892 A MX2010004892 A MX 2010004892A MX 2010004892 A MX2010004892 A MX 2010004892A MX 2010004892 A MX2010004892 A MX 2010004892A
Authority
MX
Mexico
Prior art keywords
viral infections
combination therapy
persistent viral
treat persistent
treat
Prior art date
Application number
MX2010004892A
Other languages
English (en)
Inventor
David Brooks
Michael B A Oldstone
Original Assignee
Scripps Research Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Research Inst filed Critical Scripps Research Inst
Publication of MX2010004892A publication Critical patent/MX2010004892A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/11011—Alpharetrovirus, e.g. avian leucosis virus

Abstract

La presente invención preside terapias de combinación para tratar infecciones virales persistentes; en particular, se proveen combinaciones de vacunas e IL-10 o antagonistas del receptor IL-10 (IL-10R) para aclarar dichas infecciones.
MX2010004892A 2007-10-31 2008-10-29 Terapia de combinacion para tratar infecciones virales persistentes. MX2010004892A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US98410307P 2007-10-31 2007-10-31
PCT/US2008/081614 WO2009058888A1 (en) 2007-10-31 2008-10-29 Combination therapy to treat persistent viral infections

Publications (1)

Publication Number Publication Date
MX2010004892A true MX2010004892A (es) 2010-08-10

Family

ID=40263257

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010004892A MX2010004892A (es) 2007-10-31 2008-10-29 Terapia de combinacion para tratar infecciones virales persistentes.

Country Status (6)

Country Link
US (1) US20110008332A1 (es)
EP (1) EP2214703A1 (es)
JP (1) JP2011502163A (es)
CA (1) CA2704038A1 (es)
MX (1) MX2010004892A (es)
WO (1) WO2009058888A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7030219B2 (en) 2000-04-28 2006-04-18 Johns Hopkins University B7-DC, Dendritic cell co-stimulatory molecules
WO2010027423A2 (en) 2008-08-25 2010-03-11 Amplimmune, Inc. Compositions of pd-1 antagonists and methods of use
KR20110074850A (ko) * 2008-08-25 2011-07-04 앰플리뮨, 인크. Ｐｄ-１ 길항제 및 그의 사용 방법
WO2013134146A1 (en) * 2012-03-07 2013-09-12 The Regents Of The University Of California Methods and compositions for treating viral infections by blocking type i interferon activity
WO2014159940A1 (en) 2013-03-14 2014-10-02 Macrogenics, Inc. Bispecific molecules that are immunoreactive with immune effector cells that express an activating receptor
EP3201227A4 (en) 2014-09-29 2018-04-18 Duke University Bispecific molecules comprising an hiv-1 envelope targeting arm
CA3042867A1 (en) * 2016-11-04 2018-05-11 Memorial Sloan Kettering Cancer Center Bi-specific activators for tumor therapy
CN112601531A (zh) * 2018-06-22 2021-04-02 顺天生化股份有限公司 使用具有复合状态的细胞混合物诱导免疫耐受的抗体、以及所诱导的淋巴细胞、以及使用所诱导的淋巴细胞的细胞治疗剂和治疗法
EP3836955A4 (en) * 2018-08-15 2022-05-18 The Regents of the University of California IL-10 INHIBITION FOR VACCINES AND IMMUNOTHERAPY

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6472179B2 (en) * 1998-09-25 2002-10-29 Regeneron Pharmaceuticals, Inc. Receptor based antagonists and methods of making and using
ES2334888T3 (es) * 2000-11-28 2010-03-17 Zymogenetics, L.L.C. Receptor de citocina zcytor19.
AU2003243189B2 (en) * 2002-05-01 2008-01-24 Regeneron Pharmaceuticals, Inc. Methods of using cytokine antagonists to treat HIV infection and AIDS
US20080248067A1 (en) * 2005-04-14 2008-10-09 The University Of Queensland Immunomodulating Compositions and Uses Therefor

Also Published As

Publication number Publication date
WO2009058888A1 (en) 2009-05-07
CA2704038A1 (en) 2009-05-07
US20110008332A1 (en) 2011-01-13
EP2214703A1 (en) 2010-08-11
JP2011502163A (ja) 2011-01-20

Similar Documents

Publication Publication Date Title
MX2010004892A (es) Terapia de combinacion para tratar infecciones virales persistentes.
MX2010003117A (es) Compuestos y composiciones como moduladores de la actividad de gpr119.
PL2134704T3 (pl) Związki i kompozycje pełniące rolę modulatorów aktywności GPR119
MY161495A (en) Virus like particle compositions and methods of use
TN2012000414A1 (en) Forms of rifaximin and uses thereof
JO3065B1 (ar) مركبات وتركيبات كمعدلات لفاعلية tlr
MY161415A (en) A homeopathic formulation
PH12015500758A1 (en) Pyrrolo[3,2-d]pyrimidine derivatives for the treatment of viral infections and other diseases
IN2012DN02735A (es)
IN2012DN02730A (es)
IN2012DN00754A (es)
UA96424C2 (ru) Циклопропил амины как модуляторы н3 рецепторов гистамина
MY169159A (en) Piperidino-pyrimidine derivatives for the treatment of viral infections
MX2013006040A (es) Antagonistas del receptor de acido lisofosfatidico y su uso en el tratamiento de fibrosis.
MX2012002654A (es) Compuestos y composiciones como moduladores de la actividad de tlr.
MX2009011002A (es) Composiciones de proteccion de isquemia/reperfusion y metodos de uso.
MX2012002723A (es) Composiciones inmunogenicas que incluyen moduladores de la actividad de receptores tipo toll.
EP2493464A4 (en) METHYLSULFONYLMETHANE (MSM) FOR THE TREATMENT OF DRUG-RESISTANT MICROORGANISMS
HK1139930A1 (en) Cyclopamine lactam analogs and methods of use thereof
MX2012004078A (es) Compuestos y composiciones como moduladores de la actividad de gpr119.
MX2012000396A (es) Metodos y composiciones para uso en tartamientos celulares.
DE602007010764D1 (en) Benzamidglucokinaseaktivatoren
WO2011160024A3 (en) Compounds useful as antiviral agents, compositions, and methods of use
MX2010006206A (es) Derivados de oxindol substituidos por 5-halogeno y el uso de los mismos para el tratamiento de enfermedades dependientes de la vasopresina.
MX2009009743A (es) Polvos para reconstitucion.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal